UT Southwestern biotech company lands another $80M about 18 months after last raise

ReCode Therapeutics is gearing up for human clinical trials of its primary ciliary dyskinesia (PCD) and cystic fibrosis therapies next year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.